Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK

Publication

Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK

Earl, H. M.
;
Hiller, L.
;
Dunn, J.
;
Macpherson, I.
;
Rea, D.
;
Hughes-Davies, L.
;
McAdam, K.
;
Hall, P.
;
Mansi, J.
;
Wheatley, D.
... show 8 more

Authors

Earl, H. M.
Hiller, L.
Dunn, J.
Macpherson, I.
Rea, D.
Hughes-Davies, L.
McAdam, K.
Hall, P.
Mansi, J.
Wheatley, D.
Abraham, J. E.
Caldas, C.
Gasson, S.
O'Riordan, E.
Wilcox, M.
Miles, D.
Cameron, D. A.
Wardley, Andrew M

Affiliation

Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK;

Date

2020

Collections

All Christie Publications

Show all metadata

Files

Adobe PDF, 514.56 KB

Type

Article

Citation

Earl HM, Hiller L, Dunn J, Macpherson I, Rea D, Hughes-Davies L, et al. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. Clinical Oncology. 2020.

URI

http://hdl.handle.net/10541/623242